[Long-term results after endoscopic subureteral injection for VUR using dextranomer/hyaluronic acid copolymer : a five years experience]
- PMID: 20063087
- DOI: 10.1007/s00120-009-2188-9
[Long-term results after endoscopic subureteral injection for VUR using dextranomer/hyaluronic acid copolymer : a five years experience]
Abstract
Background: A number of bulking agents have been used for the endoscopic correction of vesicoureteral reflux in children. We present the long-term results of endoscopic use of dextranomer/hyaluronic acid copolymer (Deflux) for VUR grade I-IV in children.
Patients and methods: Between 2004 and 2008, 21 children underwent endoscopic subureteral injection of Deflux in 30 ureters as an outpatient procedure. Twelve children had a unilateral reflux (two duplicated systems) and nine had a bilateral reflux. The median age was 5 years (6 months to 14.9 years). Six weeks postoperatively a voiding cystourethrogram (VCUG) was performed. This study examined the disappearance of VUR and urinary tract infection (UTI) as well as the quality of life (parents' questionnaire) during long-term follow-up.
Results: No intra- and postoperative complications were noticed. In 25 ureters (83%) VCUG showed no VUR 6 weeks postoperatively. In three children a second injection was done (two were successful). After a median follow-up of 2.5 years 27 ureters in 17 children (90%) had no UTI and VUR. The results of the questionnaire regarding quality of life were very good in the successfully treated children and the parents would choose the same treatment option again.
Conclusion: Subureteral injection of Deflux for children with VUR is an effective treatment option for VUR with a low complication rate.
Similar articles
-
Long-term results after endoscopic VUR-treatment using dextranomer / hyaluronic acid copolymer - 5-year experience in a single-center.Cent European J Urol. 2011;64(2):84-6. doi: 10.5173/ceju.2011.02.art7. Epub 2011 Jun 2. Cent European J Urol. 2011. PMID: 24578870 Free PMC article.
-
Prospective comparison and 1-year follow-up of a single endoscopic subureteral polydimethylsiloxane versus dextranomer/hyaluronic acid copolymer injection for treatment of vesicoureteral reflux in children.Urology. 2002 Nov;60(5):894-7; discussion 898. doi: 10.1016/s0090-4295(02)01903-9. Urology. 2002. PMID: 12429323 Clinical Trial.
-
Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: does bulking substance matter?J Pediatr Urol. 2015 Apr;11(2):90.e1-5. doi: 10.1016/j.jpurol.2014.12.009. Epub 2015 Mar 2. J Pediatr Urol. 2015. PMID: 25791422
-
[Therapeutic options for primary vesicoureteral reflux: endoscopic vs open surgical approach].Urologe A. 2012 Mar;51(3):352-6. doi: 10.1007/s00120-012-2805-x. Urologe A. 2012. PMID: 22350015 Review. German.
-
Endoscopic treatment of vesicoureteral reflux using dextranomer hyaluronic acid copolymer.J Pediatr Urol. 2008 Jun;4(3):221-8. doi: 10.1016/j.jpurol.2007.11.015. Epub 2008 Mar 5. J Pediatr Urol. 2008. PMID: 18631931 Review.
Cited by
-
The impact of vesicoureteral reflux treatment on the incidence of urinary tract infection.Pediatr Nephrol. 2012 Apr;27(4):529-38. doi: 10.1007/s00467-011-1809-x. Epub 2011 Mar 6. Pediatr Nephrol. 2012. PMID: 21380627 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources